TP53 and hepatocellular carcinoma: Our analysis of IPA-predicted inhibition of TP53 is consistent with the studies on hepatocellular carcinoma cells (HCC) that showed metformin downregulated TP53 via through AMPK-SIRT1 pathway in the presence of high glucose [50].